Last reviewed · How we verify
Recombinant Fowlpox-GM-CSF
At a glance
| Generic name | Recombinant Fowlpox-GM-CSF |
|---|---|
| Also known as | rF-GMCSF |
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site reaction
- SGOT (AST) (serum glutamic oxaloacetic transaminase) (aspartate aminotransferase)
- Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)
- Fatigue (lethargy, malaise, asthenia)
- Hypoalbuminemia
- Myalgia (muscle pain)
- Hemoglobin
- Creatinine
- SGPT (ALT) (serum glutamic pyruvic transaminase) (alanine aminotransferase)
- Hyperglycemia
- Cough
- Alkaline phosphatase
Key clinical trials
- Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (PHASE1)
- Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer (PHASE2)
- Sequential Vaccinations in Prostate Cancer Patients (PHASE1, PHASE2)
- Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors (PHASE1)
- A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy (PHASE1)
- 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer (PHASE2)
- A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer (PHASE2)
- Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Fowlpox-GM-CSF CI brief — competitive landscape report
- Recombinant Fowlpox-GM-CSF updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI